Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care. 

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer  

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Updates on HER2-Directed ADCs Across Solid Tumors

Video Series

ADCs Targeting HER2+ Gynecologic Cancers

Video content above is prompted by the following:

What is the potential for T-DXd in other gynecologic cancers?

Videos

Vijayakrishna Gadi, MD, PhD, sets the stage for a discussion around HER2-directed ADCs in the solid tumor space.

Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.

Assessing HER2 Status Across Tumor Types

Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.

ADCs Targeting HER2+ Breast Cancer

Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of  results from the DESTINY-PanTumor02 trial.

Dr  Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.

Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.

ADCs Targeting GI Cancers

Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.

ADCs Targeting HER2+ Lung Cancer

A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm. 

Impact of ADCs on Brain Metastases

A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers

ADCs Targeting HER2+ GU Cancers

A panel of experts discuss the challenges of testing for HER2-low access  solid tumor types. 

Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.

The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.

Managing ILD and Pneumonitis Risk From ADCs

Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.

Managing Toxicities in Short- and Long-Term Treatment with ADCs

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Managing Hematologic AEs Associated with ADC Treatments

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

Management of Emetogenicity of Antibody-Drug Conjugates

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

ADC Sequencing

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

Emerging ADCs in Development

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

The Future for HER2-Directed ADCs

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

ADCs Targeting HER2+ Gynecologic Cancers

EP: 1.Assessing HER2 Status Across Tumor Types

EP: 2.ADCs Targeting HER2+ Breast Cancer

EP: 3.ADCs Targeting HER2+ Gynecologic Cancers

EP: 4.Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

EP: 5.ADCs Targeting GI Cancers

EP: 6.ADCs Targeting HER2+ Lung Cancer

EP: 7.Impact of ADCs on Brain Metastases

EP: 8.ADCs Targeting HER2+ GU Cancers

EP: 9.Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

EP: 10.The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

EP: 11.Managing ILD and Pneumonitis Risk From ADCs

EP: 12.Managing Toxicities in Short- and Long-Term Treatment with ADCs

EP: 13.Managing Hematologic AEs Associated with ADC Treatments

EP: 14.Management of Emetogenicity of Antibody-Drug Conjugates

EP: 15.ADC Sequencing

EP: 16.Emerging ADCs in Development

EP: 17.Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

EP: 18.The Future for HER2-Directed ADCs

EP: 19.Key Takeaways and Closing Thoughts on ADCs

Latest Conference Coverage